Compare First Solar, Inc. (FSLR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Neurocrine Biosciences Inc — how do they compare? First Solar, Inc. trades at $177.82 (market cap $19.22B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: First Solar, Inc. is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Neurocrine Biosciences Inc for 23 Days on average.
| FSLR | NBIX | |
|---|---|---|
Market Cap | $19.22B | $14.36B |
Volume | 2,067,793 | 1,237,180 |
Sector | Energy | Health |
52-Week High | $318.30 | $185.50 |
52-Week Low | $172.11 | $123.10 |
Typical Hold Time | 76 Days | 23 Days |
Enterprise Value | $17.69B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $178.85, down 0.71% on the day amid a bearish technical signal, though it holds above key support at $175. The company reported strong fundamentals with 2025 revenue of $5.22B and net income of $1.53B, supported by robust operating cash flow of $2.06B. Recent news includes a patent infringement lawsuit filed against JA Solar, which briefly lifted the stock, but sector-wide pressures from high borrowing costs have contributed to recent declines.
The outlook remains mixed: analyst consensus is a 'Moderate Buy' with a $267.59 price target, signaling significant upside potential, but technical indicators and solar sector headwinds pose near-term risks. Investment opportunity lies in FSLR's attractive valuation (P/E of 11.03) and profitability (ROE 18.51%), though investors must weigh competitive and macroeconomic challenges.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
